Endothelial injury in renal antibody-mediated allograft rejection: A schematic view based on pathogenesis

Transplantation

Volumn 95, Issue 9, 2013, Pages 1073-1083

  Drachenberg, Cinthia B ^a   Papadimitriou, John C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Accommodation; C4d; Capillaritis; Complement; Donor specific antibody; Endothelial cell activation; Glomerular basement membrane remodeling; Glomerulitis; Membrane attack complex; Thrombotic microangiopathy; Transplant arteriopathy; Transplant glomerulopathy

Indexed keywords

ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; ENDOTHELIAL CELL GROWTH FACTOR; MITOGENIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOAGULANT; UNCLASSIFIED DRUG;

ANTIBODY MEDIATED REJECTION; CAPILLARITIS; CELL ACTIVATION; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CELL REGENERATION; CELL STRUCTURE; CELL SURVIVAL; CELL SWELLING; CYTOLYSIS; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; EXTRACELLULAR MATRIX; GLOMERULITIS; GLOMERULOPATHY; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KIDNEY BLOOD VESSEL; KIDNEY TUBULE CAPILLARY; LYTIC ENDOTHELIUM INJURY; MACROPHAGE; MICROVASCULATURE; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUBLYTIC ENDOTHELIUM INJURY; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSPLANT GLOMERULOPATHY;

ANIMALS; ANTIBODIES; CELL PROLIFERATION; COMPLEMENT C4B; ENDOTHELIAL CELLS; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MACROPHAGES; PEPTIDE FRAGMENTS; THROMBOTIC MICROANGIOPATHIES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84877576073     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827e6b45     Document Type: Review

References (91)

1. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012; 93: 751.
2. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibodymediated rejection workshop. Am J Transplant 2011; 11: 896.
3. Cosio FG, Lager DJ, Lorenz EC, et al. Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation 2010; 89: 1088.
4. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:520.
5. Haas M. Pathologic features of antibody-mediated rejection in renal allografts: an expanding spectrum. Curr Opin Nephrol Hypertens 2012; 21: 264.
6. Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 2215.
7. Papadimitriou JC, Drachenberg CB, Munivenkatappa R, et al. Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010; 90: 1478.
8. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
9. Wavamunno MD, O'Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7: 2757.
10. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012; 93:1
11. Fahim T, Bohmig GA, Exner M, et al. The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries. Am J Transplant 2007; 7: 385
12. Gibson IW, Gwinner W, Brocker V, et al. Peritubular capillaritis in renal allografts: prevalence, scoring system, reproducibility and clinicopathological correlates. Am J Transplant 2008; 8: 819
13. Jindra PT, Jin YP, Rozengurt E, et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008; 180: 2357.
14. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, analysis using the Banff grading schema. Transplantation 1996; 61: 1586.
15. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8.
16. Mengel M, Husain S, Hidalgo L, et al. Phenotypes of antibodymediated rejection in organ transplants. Transpl Int 2012; 25: 611.
17. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011 ; 11: 2405.
18. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibodymediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218.
19. Gloor J, Cosio F, Lager DJ, et al. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008; 8: 1367.
20. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15: 42
21. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
22. Mengel M, Bogers J, Bosmans JL, et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005; 5: 1050.
23. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
24. Grafft CA, Cornell LD, Gloor JM, et al. Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 2010; 25: 307.
25. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anticlass I-mediated rejection. Transplantation 1990; 49:85.
26. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807.
27. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 2011; 11: 2123.
28. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
29. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
30. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9: 1826.
31. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832.
32. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
33. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743.
34. Kokko KE, Colvin RB. Below the waterlineVthe danger of de novo donor-specific HLA antibodies. Am J Transplant 2012; 12: 1077.
35. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103.
36. Weinstein D, Braun WE, Cook D, et al. Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft. Am J Transplant 2005; 5: 2576.
37. Meehan SM, Kremer J, Ali FN, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol 2011; 6: 395.
38. Blume OR, Yost SE, Kaplan B. Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes. J Transplant 2012; 2012: 201754.
39. Dean PG, Park WD, Cornell LD, et al. Intragraft gene expression in positive crossmatch kidney allografts: ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant 2012; 12: 1551.
40. Yamada K, Gianello PR, Ierino FL, et al. Role of the thymus in transplantation tolerance in miniature swine: II. Effect of steroids and age on the induction of tolerance to class I mismatched renal allografts Transplantation 1999; 67: 458.
41. Ziegler ME, Souda P, Jin YP, et al. Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PLoS One 2012; 7: e29472.
42. Greep RW, Weiss L. Histology. 3rd ed. New York: McGraw-Hill Book Co.; 1973.
43. Liptak P, Kemeny E, Morvay Z, et al. Peritubular capillary damage in acute humoral rejection: an ultrastructural study on human renal allografts. Am J Transplant 2005; 5: 2870.
44. Ihrcke NS, Platt JL. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol 1996; 168: 625.
45. Ihrcke NS, Wrenshall LE, Lindman BJ, et al. Role of heparan sulfate in immune system-blood vessel interactions. Immunol Today 1993; 14: 500.
46. Brunn GJ, Saadi S, Platt JL. Differential regulation of endothelial cell activation by complement and interleukin 1alpha. Circ Res 2006; 98: 793.
47. Wehner J, Morrell CN, Reynolds T, et al. Antibody and complement in transplant vasculopathy. Circ Res 2007; 100: 191.
48. Papadimitriou JC, Ramm LE, Drachenberg CB, et al. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J Immunol 1991; 147: 212.
49. Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 2011; 51:45.
50. Saadi S,Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J 2002; 16: 849.
51. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol 2006; 1: 415.
52. Halloran PF, Schlaut J, Solez K, et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550.
53. Forbes RD, Guttmann RD. Evidence for complement-induced endothelial injury in vivo: a comparative ultrastructural tracer study in a controlled model of hyperacute rat cardiac allograft rejection. Am J Pathol 1982; 106: 378.
54. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol 2004; 172: 5143.
55. Saadi S, Platt JL. Humoral rejection and endothelial cell activation, 2001. Xenotransplantation 2002; 9: 239.
56. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 1464.
57. Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001; 91: 1487-500.
58. Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995; 181:21.
59. D'Amore PA. Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 1992; 6:1.
60. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985.
61. Drachenberg CB, Steinberger E, Hoehn-Saric E, et al. Specificity of intertubular capillary changes: comparative ultrastructural studies in renal allografts and native kidneys. Ultrastruct Pathol 1997; 21: 227.
62. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteriaVan addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
63. Aiello FB, Furian L, Della Barbera M, et al. Glomerulitis and endothelial cell enlargement in C4d(+) and C4d(-) acute rejections of renal transplant patients. Hum Pathol 2012; 43: 2157.
64. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
65. Tedesco F, Pausa M, Nardon E, et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619.
66. Kuo HH, Morrell CN, Baldwin WM 3rd. Alloantibody induced platelet responses in transplants: potent mediators in small packages. Hum Immunol 2012; 73: 1233.
67. Morrell CN, Murata K, Swaim AM, et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res 2008; 102: 777.
68. Meehan SM, Limsrichamrern S, Manaligod JR, et al. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol 2003; 34: 533.
69. Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010; 10: 1804.
70. Kilgore KS, Schmid E, Shanley TP, et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997; 150: 2019.
71. Baldwin WM 3rd, Valujskikh A, Fairchild RL. Antibody-mediated rejection: emergence of animal models to answer clinical questions. Am J Transplant 2010; 10: 1135.
72. Sun Q, Zhang M, Xie K, et al. Endothelial injury in transplant glomerulopathy is correlated with transcription factor T-bet expression. Kidney Int 2012; 82: 321.
73. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563.
74. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody- mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168.
75. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628.
76. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473.
77. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13:2371.
78. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982.
79. Hamer R,Molostvov G, LoweD, et al.Human leukocyte antigen-specific antibodies and gamma-interferon stimulate human microvascular and glomerular endothelial cells to produce complement factor c4. Transplantation 2012; 93: 867.
80. Galvani S, Trayssac M, Auge N, et al. A key role for matrix metalloproteinases and neutral sphingomyelinase-2 in transplant vasculopathy triggered by anti-HLA antibody. Circulation 2011; 124: 2725.
81. Lynch RJ, Platt JL. Escaping from rejection. Transplantation 2009; 88: 1233.
82. Lynch RJ, Platt JL. Accommodation in renal transplantation: unanswered questions. Curr Opin Organ Transplant 2010; 15: 481.
83. Park WD, Grande JP, Ninova D, et al. Accommodation in ABOincompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3: 952.
84. Platt JL. Accommodation: how you see it, how you don't. Am J Transplant 2011; 11: 2007.
85. Raghavaiah S, Stegall MD. New therapeutic approaches to antibodymediated rejection in renal transplantation. Clin Pharmacol Ther 2011; 90: 310.
86. Chen Song S, Zhong S, Xiang Y, et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 2011; 11: 2057.
87. Dragun D, Catar R, Kusch A. Non-HLA-antibodies targeting angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 2012; 73: 1282.
88. Papadimitriou JC, Carney DF, Shin ML. Inhibitors of membrane lipid metabolism enhance complement-mediated nucleated cell killing through distinct mechanisms. Mol Immunol 1991; 28: 803.
89. Kriz W. Fenestrated glomerular capillaries are unique. J Am Soc Nephrol 2008; 19: 1439.
90. Baid-Agrawal S, Farris AB 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879.
91. Guo S, Wietecha TA, Hudkins KL, et al. Macrophages are essential contributors to kidney injury in murine cryoglobulinemic membranoproliferative glomerulonephritis. Kidney Int 2011; 80: 946.